目的 評(píng)價(jià)靈寶護(hù)心丹治療心動(dòng)過緩型心律失常的有效性和安全性。方法 選取2020年11月—2022年12月上海市第六人民醫(yī)院收治的竇性心動(dòng)過緩患者100例，隨機(jī)分為對(duì)照組（50例）和治療組（50例）。對(duì)照組患者口服二羥丙茶堿片，100 mg/次，3次/d；治療組患者口服靈寶護(hù)心丹，4丸/次，3次/d。兩組患者治療12周。觀察兩組患者臨床療效，比較治療前后兩組患者中醫(yī)證候評(píng)分，動(dòng)態(tài)心電圖指標(biāo)平均心率、總心率和最慢心率，及不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組和治療組總有效率分別為91.11%、97.87%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療第4、8、12周后，兩組中醫(yī)癥候評(píng)分均顯著降低（P＜0.05）；治療組患者中醫(yī)證候評(píng)分均低于同期對(duì)照組（P＜0.05）。治療第4、8、12周后，兩組平均心率、總心率和最慢心率均顯著提高（P＜0.05）；治療8、12周后，治療組平均心率、總心率和最慢心率顯著高于同期對(duì)照組（P＜0.05）。治療組不良反應(yīng)總發(fā)生率（2.13%）顯著低于對(duì)照組（11.11%，P＜0.05）。結(jié)論 靈寶護(hù)心丹對(duì)心動(dòng)過緩型心律失?；颊呔哂休^好療效，且安全性較好，長(zhǎng)期使用優(yōu)于二羥丙茶堿。

Objective To evaluate the clinical efficacy and safety of Lingbao Huxindan in treatment of bradycardia arrhythmia. Methods Patients (100 cases) with bradycardia arrhythmia in Shanghai Sixth People's Hospital from November 2020 to December 2022 were randomly divided into control (50 cases) and treatment (50 cases) group. Patients in the control group were po administered with Diprophylline Tablets, 100 mg/time, three times daily. Patients in the treatment group were po administered with Lingbao Huxindan on the basis of the control group, 4 pills/time, three time daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical evaluations were evaluated, the TCM syndrome scores, dynamic electrocardiogram indexes and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate was 97.87% in the treatment group and 91.11% in the control group, the difference between the two groups was statistically significant (P < 0.05). After 4, 8 and 12 weeks of treatment, TCM symptom scores in both groups were significantly decreased (P < 0.05). The TCM syndrome scores in the treatment group were lower than those in the control group (P < 0.05). After 4, 8 and 12 weeks of treatment, the mean heart rate, total heart rate and minimum heart rate of the two groups were significantly increased (P < 0.05). After 8 and 12 weeks of treatment, the mean heart rate, total heart rate and minimum heart rate in the treatment group were significantly higher than those in the control group (P < 0.05). The total incidence of adverse reactions in the treatment group (2.13%) was significantly lower than that in the control group (11.11%, P < 0.05). Conclusion Lingbao Huxindan has a good curative effect and safety in patients with bradycardia arrhythmias, and its long-term use is better than that of dihydroxypropylline.

R972